March 28, 2018 / 12:22 PM / 6 months ago

BRIEF-Cynata Therapeutics says FDA Grants orphan drug designation to cymerus msc product, cyp-001

March 28 (Reuters) - Cynata Therapeutics Ltd:

* FDA GRANTS ORPHAN DRUG DESIGNATION TO CYNATA’S LEAD CYMERUS™ MSC PRODUCT, CYP-001

* CYNATA THERAPEUTICS - U.S. FDA GRANTED CO ORPHAN DRUG DESIGNATION FOR CYP-001 FOR TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below